RT Journal Article
T1 Once-Weekly Semaglutide Use in Patients with Type 2 Diabetes: Results from the SURE Spain Multicentre, Prospective, Observational Study.
A1 Bellido, Virginia
A1 Abreu Padín, Cristina
A1 Catarig, Andrei-Mircea
A1 Clark, Alice
A1 Barreto Pittol, Sofía
A1 Delgado, Elias
K1 HbA1c
K1 SURE study
K1 body weight
K1 glucagon-like peptide-1 receptor agonist
K1 real-world evidence
K1 semaglutide
K1 type 2 diabetes
AB Type 2 diabetes (T2D) is a complex disease for which an individualised treatment approach is recommended. Once-weekly (OW) semaglutide is a glucagon-like peptide-1 receptor agonist approved for the treatment of insufficiently controlled T2D. The aim of this study was to investigate the use of OW semaglutide in adults with T2D in a real-world context. SURE Spain, from the 10-country SURE programme, was a prospective, multicentre, open-label, observational study, approximately 30 weeks in duration. Adults with T2D and ≥1 documented HbA1c value ≤12 weeks before semaglutide initiation were enrolled. Change in HbA1c from baseline to end of study (EOS) was the primary endpoint, with change in body weight (BW), waist circumference, and patient-reported outcomes as secondary endpoints. Of the 227 patients initiating semaglutide, 196 (86.3%) completed the study on-treatment with semaglutide. The estimated mean changes in HbA1c and body weight between baseline and EOS were -1.3%-points (95% confidence interval (CI) -1.51;-1.18%-points) and -5.7 kg (95% CI -6.36;-4.98 kg). No new safety concerns were identified. Therefore, in routine clinical practice in Spain, OW semaglutide was shown to be associated with statistically significant and clinically relevant reductions in HbA1c and BW in adults with T2D.
SN 2077-0383
YR 2022
FD 2022-08-23
LK http://hdl.handle.net/10668/21336
UL http://hdl.handle.net/10668/21336
LA en
DS RISalud
RD Apr 10, 2025